Headquartered in Chengdu, China, Jinxin Fertility (Stock code: 1951) is an assisted reproductive services (“ARS”) provider in China and the U.S. with a history that can be traced back to 2003. Jinxin Fertility owns and operates four ARS hospitals in Chengdu, Wuhan, and Shenzhen in China, and Jinrui Medical Center in Laos which was acquired in 2020. Jinxin jointly manages an in-vitro fertilization (“IVF”) center in Chengdu, and manages a leading full-service ARS provider in the U.S. Jinxin Fertility also owns and operates a laboratory and a surgical center in the U.S.

According to the annual report of Jinxin Fertility for the year ended December 31, 2019, Jinxin Fertility ranked first in 2019 in terms of the number of IVF treatment cycles in Sichuan province and Shenzhen, Guangdong province in China and in the western region of the United States. Jinxin Fertility was one of the most subscribed Hong Kong initial public offerings during the first half of 2019, and one of the largest healthcare service initial public offerings on the Stock Exchange in terms of valuation at the time of listing. LionRock invested in Jinxin Fertility as a pre-IPO investor in April 2018.